Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"RGS is actively seeking Japanese partners for its adipose-derived mesenchymal stem cell osteoarthritis drug, Progenza." (8/5/15) Regeneus Ltd. - The Life Sciences Report Interview with Colin Lee Novick Moreá>
Sanjiv S. Agarwala, MD
Dr. Sanjiv Agarwala is chief of medical oncology and hematology at St. Lukeĺs Cancer Center in Bethlehem, PA, and professor of medicine at Temple University School of Medicine in Philadelphia. He is nationally and internationally recognized as an expert in the research and treatment of melanoma and cutaneous malignancies. He graduated from the University of Bombay and did residencies and fellowships at the University of Bombay in India, Dunedin University in New Zealand and University of Pittsburgh in Pittsburgh, PA. Dr. Agarwala has special interest and expertise in immunotherapy for cancer. He has been principal investigator for several clinical trials involving immunotherapy and targeted therapy for melanoma and other malignancies. He has written more than 100 publications and book chapters on melanoma and other research areas. He is board-certified in oncology, hematology and internal medicine, and is an active member of several professional and scientific societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, the European Society of Medical Oncology and the Society for Melanoma Research.
New Melanoma Therapies Are Ready for Prime Time: Sanjiv Agarwala (4/29/14) Melanoma confronts patients and their physicians with unique barriers to treatment and successful outcomes. In this interview with The Life Sciences Report, Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's University Hospital, illuminates some of the new paradigms being developed in the treatment of this deadly skin cancer. Along the way, he spotlights interesting companies working in the field.
"PVCT's PV-10 produced not only a local shrinkage of tumor, but also significant responses in noninjected lesions." (4/29/14) Provectus Biopharmaceuticals Inc. - The Life Sciences Report Interview with Sanjiv Agarwala Moreá>
"When I can get potential blue-sky regenerative technologies like RP's at this small valuation, I'm buying." (8/12/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Eden Rahim Moreá>